Nanosys Inc. today
announced that it has signed two agreements with Harvard University to combine
their extensive intellectual property (IP) assets to facilitate out-licensing
in two areas: nanowire-based biosensors and nanowire-based non-volatile memories.
The IP is available for out-licensing to any interested third parties. The technologies
being made available originate from the laboratory of Dr. Charles Lieber (Mark
Hymen Professor of Chemistry at Harvard University), as well as many other nanotech
researchers at Nanosys and other universities associated with Nanosys. The IP
on offer includes Nanosys' extensive portfolio covering all aspects of nanowire
production, functionalization, material interface technologies, fabrication
technologies, basic devices using nanostructures, applications and architectures,
and Harvard's portfolio of nanowire-based biosensor and non-volatile memory
"The agreements between Nanosys and Harvard reflect an innovative strategy
to facilitate the development of two novel disruptive technologies," said
Isaac T. Kohlberg, Harvard University's Senior Associate Provost and Chief Technology
Development Officer. "We're delighted to be working in concert with Nanosys,
a recognized leader in the nanowire space, to identify companies interested
in acquiring rights to our innovative nanowire technologies for next-generation
biosensors and non-volatile memory."
Andrew Filler, General Counsel and Vice-President of Intellectual Property
at Nanosys, commented: "As companies are now realizing the significant
commercial value of nanotechnology to expand upon and open up new markets, our
goal is to help these companies address these markets using our intellectual
property portfolio." He added, "After developing many fundamental
technology platforms at Nanosys over the last several years, the company is
now focused on commercializing technologies in core business areas including
solid state lighting, electronics, energy storage and medical device applications.
Our nanotechnology licensing program complements our core business focus, thereby
providing the market with a convenient licensing option to our fundamental patent
portfolio in areas that we are not fully exploiting ourselves."